Abstract
α-Synuclein (a-syn) oligomers and fibrils are behind neurodegeneration in Parkinson's disease (PD), but therapeutically targeting them is challenging. Amphipathic and cationic helical peptides inhibit amyloid formation and suppress neurotoxicity by selectively binding the solvent-accessible regions in these toxic species. Can endogenous peptides, like LL-37, constitute a new therapeutic paradigm in PD?
| Original language | English |
|---|---|
| Pages (from-to) | 641-644 |
| Number of pages | 4 |
| Journal | Trends in Biochemical Sciences |
| Volume | 47 |
| Issue number | 8 |
| Early online date | 19 Feb 2022 |
| DOIs | |
| Publication status | Published - 1 Aug 2022 |
Keywords
- amyloid fibril
- disease-modifying therapy
- LL-37
- oligomer
- Parkinson's disease
- α-synuclein